160 related articles for article (PubMed ID: 34756762)
1. Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery.
Horie K; Matsuda T; Yamashita K; Hasegawa H; Utsumi M; Urakawa N; Kanaji S; Oshikiri T; Kakeji Y
Eur J Surg Oncol; 2022 Apr; 48(4):850-856. PubMed ID: 34756762
[TBL] [Abstract][Full Text] [Related]
2. Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma.
Levolger S; van Vledder MG; Alberda WJ; Verhoef C; de Bruin RWF; IJzermans JNM; Burger JW
Clin Nutr; 2018 Oct; 37(5):1728-1735. PubMed ID: 28756039
[TBL] [Abstract][Full Text] [Related]
3. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
[TBL] [Abstract][Full Text] [Related]
4. The modified Glasgow prognostic score is a reliable predictor of oncological outcomes in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy.
Shimada A; Matsuda T; Sawada R; Hasegawa H; Yamashita K; Harada H; Urakawa N; Goto H; Kanaji S; Oshikiri T; Kakeji Y
Sci Rep; 2023 Oct; 13(1):17111. PubMed ID: 37816855
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy.
Takeda Y; Akiyoshi T; Matsueda K; Fukuoka H; Ogura A; Miki H; Hiyoshi Y; Nagasaki T; Konishi T; Fujimoto Y; Fukunaga Y; Ueno M
PLoS One; 2018; 13(4):e0195406. PubMed ID: 29630652
[TBL] [Abstract][Full Text] [Related]
6. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a retrospective study.
Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Kishikawa J; Ishii H; Yokoyama Y; Nagai Y; Anzai H; Sonoda H; Oba K; Ishihara S
Int J Clin Oncol; 2022 Jan; 27(1):141-153. PubMed ID: 34741193
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single-institution study with propensity score-matched comparative analysis.
Sun XY; Cai SH; Xu L; Luo D; Qiu HZ; Wu B; Lin GL; Lu JY; Zhang GN; Xiao Y
Asia Pac J Clin Oncol; 2020 Jun; 16(3):142-149. PubMed ID: 32031326
[TBL] [Abstract][Full Text] [Related]
8. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
9. Alb-dNLR Score as a Novel Prognostic Marker for Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy.
Nakanishi T; Matsuda T; Yamashita K; Hasegawa H; Sawada R; Harada H; Urakawa N; Goto H; Kanaji S; Oshikiri T; Kakeji Y
Anticancer Res; 2024 Jan; 44(1):229-237. PubMed ID: 38159989
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapy.
Jang JY; Oh D; Noh JM; Sun JM; Kim HK; Shim YM
J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1167-1176. PubMed ID: 38613258
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
12. Does prehabilitation modify muscle mass in patients with rectal cancer undergoing neoadjuvant therapy? A subanalysis from the REx randomised controlled trial.
Moug SJ; Barry SJE; Maguire S; Johns N; Dolan D; Steele RJC; Buchan C; Mackay G; Anderson AS; Mutrie N
Tech Coloproctol; 2020 Sep; 24(9):959-964. PubMed ID: 32564236
[TBL] [Abstract][Full Text] [Related]
13. Is radiological psoas muscle area measurement a predictor of postoperative complications after rectal resection for rectal cancer? A retrospective study.
Uehara H; Yamazaki T; Iwaya A; Kameyama H; Utsumi S; Harada R; Komatsu M; Hirai M; Kubota A; Katada T; Kobayashi K; Sato D; Yokoyama N; Kuwabara S; Otani T
Surg Today; 2022 Feb; 52(2):306-315. PubMed ID: 34309711
[TBL] [Abstract][Full Text] [Related]
14. Patient's Skeletal Muscle Radiation Attenuation and Sarcopenic Obesity are Associated with Postoperative Morbidity after Neoadjuvant Chemoradiation and Resection for Rectal Cancer.
Berkel AEM; Klaase JM; de Graaff F; Brusse-Keizer MGJ; Bongers BC; van Meeteren NLU
Dig Surg; 2019; 36(5):376-383. PubMed ID: 29898443
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
Yoon HG; Oh D; Ahn YC; Noh JM; Pyo H; Cho WK; Song YM; Park M; Hwang NY; Sun JM; Kim HK; Zo JI; Shim YM
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290037
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
Xu L; Cai S; Xiao T; Chen Y; Qiu H; Wu B; Lin G; Sun X; Lu J; Zhou W; Xiao Y
Colorectal Dis; 2017 Jul; 19(7):O263-O271. PubMed ID: 28603932
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.
Tokuhara K; Ueyama Y; Nakatani K; Yoshioka K; Kon M
World J Surg Oncol; 2016 Apr; 14():136. PubMed ID: 27129578
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Lin H; Wang L; Zhong X; Zhang X; Shao L; Wu J
World J Surg Oncol; 2021 May; 19(1):141. PubMed ID: 33952287
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of Nuclear β-Catenin before Starting Treatment Could Potentially Predict the Therapeutic Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer].
Miyako S; Matsuda T; Kato T; Shimizu M; Sawada R; Harada H; Urakawa N; Goto H; Hasegawa H; Kanaji S; Yamashita K; Oshikiri T; Kakeji Y
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1370-1373. PubMed ID: 38303278
[TBL] [Abstract][Full Text] [Related]
20. Timing to achieve the best recurrence-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: experience in a large-volume center in China.
Wang X; Zheng Z; Zhu H; Yu Q; Huang S; Lu X; Huang Y; Chi P
Int J Colorectal Dis; 2021 May; 36(5):1007-1016. PubMed ID: 33398511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
